Days to partner up
Roche is looking for new partners in the innovative Norwegian life science scene.
Roche is one of the largest pharmaceutical companies in the world with about 800 ongoing clinical trials. Within cancer research and development, this translates into about 500 clinical trials for many different types of cancer. Roche is a member in Oslo Cancer Cluster.
Read more about Roche’s cancer research
As a part of Roche’s scouting for new innovative collaborations, the company arranged two partnering days in the beginning of December together with Oslo Cancer Cluster and the health cluster Norway Health Tech. Together, we welcomed start-ups, biotechs, academic researchers, clinicians, politicians, innovation agencies, students and other interested parties to a two day open meeting.
Partnering with companies
The first day was at the at Oslo Cancer Cluster Innovation Park and the second day was at Oslo Science Park.
Growing life sciences in Norway is important to Oslo Cancer Cluster, and the larger pharmaceutical companies’ commitment to working with local stakeholders and local companies is an essential part of the innovative developments in this field.
Such collaborations have the potential to bring more investment to Norway and provide platforms for local companies to innovate, thrive and grow.
— What we want to do is to strengthen the collaborations and to see even more companies emerge from the exciting research going on in academia in Norway, said Jutta Heix, Head of International Affairs at Oslo Cancer Cluster.
Partnering with academia
Professor Johanna Olweus from the Institute for Cancer Research at Oslo University Hospital was one of the speakers. She also presented the Department of Immunology and K.G. Jebsen Center for Cancer Immunotherapy for a full auditorium at Oslo Cancer Cluster Innovation Park.
Established back in 1954, the Institute for Cancer Research at Oslo University Hospital is certainly a well established institute and their Department of Immunology is currently involved in all the clinical trial phases.
— The scientists at the institute realise the importance of collaborating with the industry in order to get results out to the patients, Olweus said, and showed some examples of scientist-led innovations from the institute, including the Department of Cancer Immunology.
In this story, you can read more about how science from Oslo University Hospital is turning into innovation that truly helps cancer patients.